ArticleProceedings of the National Academy of Sciences of the United States of America2025
A molecular probe for detecting cholinesterase activity in MRI.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A "turn-off" photoacoustic contrast for urokinase-type plasminogen activator activity.npj biomedical innovations · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cholinesterase (ChE) enzymes terminate action of the neurotransmitter acetylcholine at synapses and neuromuscular junctions throughout the body. Noninvasive strategies for monitoring these enzymes could be important for studying basic biology of cholinergic systems and disorders that affect their function. To address this goal, we developed an imaging probe that allows activity of ChE to be detected using MRI. The probe, called ChERT, undergoes enzymatic processing that reduces its solubility, promoting accumulation near sites of cholinesterase activity. Following wide-field brain delivery, ChERT produces MRI contrast changes in brain regions known to be enriched in cholinesterases; these are suppressed in the presence of a selective enzymatic inhibitor, confirming their specificity. After abdominal delivery, ChERT labels regions of the gut where ChE expression is expected. In both the brain and periphery, colocalization of ChERT with ChE could be confirmed and visualized at higher resolution by fluorescence microscopy, owing to optical properties of the probe architecture. The ChERT agent thus provides a potentially versatile basis for assessment of cholinergic phenotypes throughout the body.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.